Profiel
Frank DeRosa worked as a Senior Director of Preclinical Research at Shire Human Genetic Therapies, Inc. from 2009 to 2016.
He then worked as the Chief Technology Officer at Translate Bio, Inc. from 2019 to 2021.
Prior to his career in industry, he earned a doctorate degree from the University of California.
Eerdere bekende functies van Frank DeRosa
| Bedrijven | Functie | Einde |
|---|---|---|
| TRANSLATE BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 14-09-2021 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01-12-2016 |
Opleiding van Frank DeRosa
| University of California | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |